No Data
No Data
Express News | Mabwell Announces the Cde Approval of Novel Nectin-4 Targeting ADC to Initiate Phase III Clinical Trial for the Treatment of Cervical Cancer
Mabwell Shanghai Bioscience Gets Nod to Trial Cervical Cancer Drugs
Meiwei Bio's targeted Nectin-4 ADC innovative drug 9MW2821 has been approved by the CDE to conduct Phase III clinical trials for cervical cancer.
Shanghai, August 23, 2024 / PRNewswire / - Maiwei Biotech (688062.SH), an innovative biopharmaceutical company with a complete industry chain layout, announced that its submission to the National Medical Products Administration (NMPA) Center for Drug Evaluation (CDE) regarding the "9MW2821 Randomized, Open-label, Controlled, Multicenter Phase III Clinical Study for the Treatment of Platinum-based Chemotherapy Failure in Recurrent or Metastatic Cervical Cancer Selected by Researchers" protocol has been approved, and the Phase III clinical study for the treatment of recurrent or metastatic cervical cancer, which failed platinum-based chemotherapy, using 9MW2821 will commence.
Express News | Mabwell's Novel Nectin-4 Targeting ADC 9MW2821 Granted Breakthrough Therapy Designation by China's Nmpa
Mabwell Shanghai Bioscience's Cancer Drug Enters Drug Regulator's Breakthrough Drugs List
Maiwei Biological (688062.SH): 9MW2821 is included in the breakthrough therapy for the indication of urothelial carcinoma.
Meiwei Bio (688062.SH) announced that the company has developed the innovative drug 9MW2821 through independent intellectual property rights research and development...
No Data